Literature DB >> 9197213

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.

M H Chang1, C J Chen, M S Lai, H M Hsu, T C Wu, M S Kong, D C Liang, W Y Shau, D S Chen.   

Abstract

BACKGROUND: A nationwide hepatitis B vaccination program was implemented in Taiwan in July 1984. To assess the effect of the program on the development of hepatocellular carcinoma, we studied the incidence of this cancer in children in Taiwan from 1981 to 1994.
METHODS: We collected data on liver cancer in children from Taiwan's National Cancer Registry, which receives reports from each of the country's 142 hospitals with more than 50 beds. Data on childhood liver cancer were also obtained from Taiwan's 17 major medical centers. To prevent the inclusion of cases of hepatoblastoma, the primary analysis was confined to liver cancers in children six years of age or older. Data were also obtained on mortality from liver cancer among children.
RESULTS: The average annual incidence of hepatocellular carcinoma in children 6 to 14 years of age declined from 0.70 per 100,000 children between 1981 and 1986 to 0.57 between 1986 and 1990, and to 0.36 between 1990 and 1994 (P<0.01). The corresponding rates of mortality from hepatocellular carcinoma also decreased. The incidence of hepatocellular carcinoma in children 6 to 9 years of age declined from 0.52 for those born between 1974 and 1984 to 0.13 for those born between 1984 and 1986 (P<0.001).
CONCLUSIONS: Since the institution of Taiwan's program of universal hepatitis B vaccination, the incidence of hepatocellular carcinoma in children has declined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9197213     DOI: 10.1056/NEJM199706263362602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  330 in total

1.  Molecular biology and the diagnosis and treatment of liver diseases.

Authors:  Howard J Worman; Lin Feng; Naoto Mamiya
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

2.  Chemopreventive effect of oltipraz on AFB(1)-induced hepatocarcinogenesis in tree shrew model.

Authors:  Yuan Li; Jian-Jia Su; Liu-Liang Qin; Chun Yang; Dan Luo; Ke-Chen Ban; TW Kensler; BD Roebuck
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

Review 3.  Promoting prevention of viral hepatitis in the African American community.

Authors: 
Journal:  J Natl Med Assoc       Date:  2003-04       Impact factor: 1.798

4.  Liver cancer in low and middle income countries.

Authors:  Andrew J Hall; Christopher P Wild
Journal:  BMJ       Date:  2003-05-10

Review 5.  Hepatocellular carcinoma: updates in primary prevention.

Authors:  Will J Fecht; Alex S Befeler
Journal:  Curr Gastroenterol Rep       Date:  2004-02

6.  Coordinated tumor immunity.

Authors:  Glenn Dranoff
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 7.  Treatment of hepatocarcinoma.

Authors:  Beatrice Gerard; Harry Bleiberg
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

Review 8.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

9.  Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations.

Authors:  Nimzing G Ladep; Shahid A Khan; Mary Me Crossey; Andrew V Thillainayagam; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

10.  American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.

Authors:  Robin T Zon; Elizabeth Goss; Victor G Vogel; Rowan T Chlebowski; Ismail Jatoi; Mark E Robson; Dana S Wollins; Judy E Garber; Powel Brown; Barnett S Kramer
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.